Home › Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma clinical trials recruiting in the U.S.
127 studies for Non-Hodgkin Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX31 studies
- New York City, NY31 studies
- Boston, MA26 studies
- Nashville, TN21 studies
- Philadelphia, PA20 studies
- Baldwin Park, CA19 studies
- Atlanta, GA18 studies
- Chicago, IL18 studies
- Milwaukee, WI18 studies
- Columbus, OH18 studies
- Washington, DC18 studies
- Dallas, TX17 studies
- Durham, NC16 studies
- Seattle, WA16 studies
- Portland, OR15 studies
- Rochester, MN14 studies
- Miami, FL14 studies
- Omaha, NE14 studies
- Denver, CO14 studies
- Cleveland, OH13 studies
- Salt Lake City, UT13 studies
- Mountain View, CA12 studies
- St. Louis, MO11 studies
- Aurora, CO11 studies
- Los Angeles, CA9 studies
- Tampa, FL9 studies
- Jacksonville, FL9 studies
- San Francisco, CA9 studies
- Cincinnati, OH9 studies
- Pittsburgh, PA8 studies
- San Diego, CA8 studies
- Baltimore, MD8 studies
- Cedar Rapids, IA8 studies
- Ann Arbor, MI8 studies
- Clifton, NJ7 studies
- Buffalo, NY7 studies
- Kansas City, MO7 studies
- Birmingham, AL7 studies
- Edison, NJ7 studies
- Queens, NY7 studies
By state
- Alabama7 studies
- Arizona14 studies
- Arkansas5 studies
- California42 studies
- Colorado20 studies
- Connecticut8 studies
- Delaware4 studies
- District of Columbia4 studies
- Florida32 studies
- Georgia21 studies
- Hawaii3 studies
- Idaho3 studies
- Illinois20 studies
- Indiana10 studies
- Iowa10 studies
- Kansas9 studies
- Kentucky5 studies
- Louisiana6 studies
- Maine4 studies
- Maryland21 studies
- Massachusetts28 studies
- Michigan13 studies
- Minnesota19 studies
- Mississippi3 studies
- Missouri10 studies
- Montana3 studies
- Nebraska15 studies
- New Jersey13 studies
- New Mexico4 studies
- New York40 studies
- North Carolina24 studies
- North Dakota3 studies
- Ohio34 studies
- Oklahoma3 studies
- Oregon15 studies
- Pennsylvania26 studies
- Rhode Island5 studies
- South Carolina5 studies
- South Dakota3 studies
- Tennessee24 studies
- Texas48 studies
- Utah14 studies
- Virginia13 studies
- Washington20 studies
- West Virginia3 studies
- Wisconsin20 studies
Recently updated studies
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RecruitingPhase 1
Up to age 75 · All sexes · Updated Oct 2, 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Oct 2, 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Oct 2, 2026 · NCT02917083Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07763210A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07582432T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Sep 30, 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05645107NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07052305A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT03223610A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07519772Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 25, 2026 · NCT05907759Epco, Zanu, Ritux for R/R FL or MZL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04002947Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 15, 2026 · NCT05798897From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.